Drugs for preventing malaria in travellers
Información
- DOI:
- https://doi.org/10.1002/14651858.CD006491.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 octubre 2009see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Enfermedades infecciosas
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
AC and FJ wrote the review, extracted the data, assessed trial eligibility and risk of bias, analysed the data, reported the outcomes, jointly drafted the discussion, and agreed the conclusions.
Sources of support
Internal sources
-
Center for Evidence‐Based Global Health, Tulane University, USA.
-
Commander Regional Forces, UK.
External sources
-
Department for International Development, UK.
Declarations of interest
AC is an investigator on one of the included trials.
Acknowledgements
The editorial base for the Cochrane Infectious Diseases Group is funded by the UK Department for International Development (DFID) for the benefit of developing countries.
Version history
| Published | Title | Stage | Authors | Version |
| 2017 Oct 30 | Mefloquine for preventing malaria during travel to endemic areas | Review | Maya Tickell‐Painter, Nicola Maayan, Rachel Saunders, Cheryl Pace, David Sinclair | |
| 2015 Oct 05 | Drugs for preventing malaria in travellers | Review | Frederique A Jacquerioz, Ashley M Croft | |
| 2009 Oct 07 | Drugs for preventing malaria in travellers | Review | Frederique A Jacquerioz, Ashley M Croft | |
| 2009 Jul 08 | Drugs for preventing malaria in travellers | Protocol | Frederique A Jacquerioz, Ashley M Croft | |
Differences between protocol and review
In the protocol, only adverse events were considered. However, a few authors used the terms 'adverse event', 'adverse effect', or 'side effect' interchangeably and loosely. For the sake of clarity, we considered two categories of adverse outcomes: 'adverse event' and 'adverse effect'. This latter category encompassed reporting by authors of 'adverse effect', 'side effect', and 'adverse event attributed to the study drug'. Both categories of adverse outcomes were further divided into any, dermatological, gastrointestinal, and neuropsychiatric adverse event or effect. We used the Uppsala Monitoring Centre's definition of an adverse event, namely "any event that may present while taking the chemoprophylaxis but which does not necessarily have a causal relationship with the drug" (Uppsala 2001) and the Cochrane Handbook's definition of an adverse effect , namely "any event for which the causal relation between the intervention and the event is at least a reasonable possibility" (Loke 2008).
We chose to report “discontinuation of study drug at any time for any reason” instead of “withdrawal due to study drug related adverse events”, to avoid selective bias. When not explicitly reported by the investigators, we extracted results for this outcome from the study flow charts and/or from the published text of the trial.
We added POMS score (McNair 1992) to the outcomes. Two trials measured this outcome, which is consistent with the objective of the review.
Cochrane guidelines for evaluating the risk of bias (i.e. methodological quality) of trials ('Risk of bias' tables) and also the quality of evidence ('Summary of findings' tables) changed between the publication of our protocol in 2007 and the preparation of this review. We updated our methods to reflect these changes.
Notes
This review replaces the previously published (now withdrawn) review: Croft AM, Garner P. Mefloquine for preventing malaria in non‐immune adult travellers. Cochrane Database of Systematic Reviews 2000 , Issue 4 . Art. No.: CD000138. DOI: 10.1002/14651858.CD000138.pub2.
